CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan, M.B., B.Ch., will present a company overview at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017, at 10:00 a.m. ET, in New York City.
A live webcast of the presentation can be accessed under “Presentations” in the Investors & Media section of the Company’s website at www.synlogictx.com. An archived webcast recording will be available on the Synlogic website for approximately 30 days.
About Synlogic™
Synlogic is pioneering the development of a
novel class of living treatments, Synthetic Biotic™ medicines, based on
its proprietary drug discovery and development platform. Synlogic’s
initial pipeline includes Synthetic Biotic medicines for the treatment
of rare genetic diseases, such as Urea Cycle Disorder (UCD) and
Phenylketonuria (PKU). In addition, the company is leveraging the broad
potential of its platform to create Synthetic Biotic medicines for the
treatment of more common diseases, including liver disease, inflammatory
and immune disorders, and cancer. Synlogic is collaborating with AbbVie
to develop Synthetic Biotic-based treatments for inflammatory bowel
disease (IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170901005270/en/
